NCT07199205Not yet recruiting
Hyperuricemia as Early Indication of CKD Progressing in Prediabetic
Hyperuricemia as a Predictor of Chronic Kidney Disease (CKD) Progression in Prediabetic Patients
Source: ClinicalTrials.gov · Last updated 30 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Chronic kidney disease (CKD) is a major global health problem, and hyperuricemia has emerged as both a consequence and a potential driver of its progression. Elevated uric acid contributes to renal impairment through oxidative stress, endothelial dysfunction, inflammasome activation, and crystal deposition. Epidemiological studies show that hyperuricemia often precedes CKD and serves as an independent predictor, with prevalence reaching up to 38% among CKD patients. Prediabetes, another growing health concern, is associated with higher serum uric acid levels and increased risk of developing both diabetes and CKD. Factors such as obesity, fatty liver, and dyslipidemia mediate this link. Clinically, higher uric acid levels are correlated with faster eGFR decline and higher risk of ESRD, with the uric acid/HDL ratio proposed as a novel risk marker. Although debate persists about whether hyperuricemia directly causes CKD, emerging genetic and epidemiological evidence supports its independent role. Given the rising prevalence of prediabetes and hyperuricemia, identifying hyperuricemia as a modifiable early predictor of CKD progression in prediabetic patients could help improve prevention, risk stratification, and management
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 150 (estimated)
- First submitted
- 19 Sept 2025
- Start date
- 1 Oct 2025
- Primary completion date
- 31 Oct 2026
- Lead sponsor
- Assiut University
- Diseases
- Chronic kidney disease
- NCT number
- NCT07199205
What you commit to
- Study type: Observational
- Planned participants: 150
- From 1 Oct 2025 to the primary completion date, 31 Oct 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of medications known to significantly affect uric acid levels (e.g., thiazide diuretics, high-dose aspirin).
Other illness
- History of gout or current use of uric acid-lowering therapy (e.g., allopurinol, febuxostat) or acute gout.
- Presence of severe comorbid conditions (e.g., malignancy, active infection, advanced liver disease).
Lab values
- Diagnosis of diabetes mellitus (fasting plasma glucose ≥126 mg/dL, HbA1c ≥6.5%).
- Established CKD stage 3 or higher (eGFR \<60 mL/min/1.73 m²).
Other
- Pregnancy or lactation.
Who the study is looking for
- Adults aged 18 years and older.
- Diagnosed with prediabetes, defined according to the American Diabetes - - - - Association (ADA) criteria (fasting plasma glucose 100-125 mg/dL, HbA1c 5.7-6.4%, or 2-hour plasma glucose 140-199 mg/dL after oral glucose tolerance test).
- Baseline estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.73 m² (CKD stages 1-2).
- Willingness to provide informed consent and comply with study procedures.
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.